Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             229 results found
no title author magazine year volume issue page(s) type
1 Adhesion molecules and gene transfer Parkes, Richard J
 2000
 69-70 2-3 p. 135-152
18 p.
 article
2 Adv. Drug Delivery Rev. Welt, Frederick G.P.
 1997
 69-70 2-3 p. 299-
1 p.
 article
3 Amphotericin B colloidal dispersion: an improved antifungal therapy Guo, Luke S.S
 2001
 69-70 2-3 p. 149-163
15 p.
 article
4 Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases Kohno, Shigeru
 1997
 69-70 2-3 p. 325-329
5 p.
 article
5 Analytical challenges in chemical-enzymatic drug targeting Prókai, László
 1994
 69-70 2-3 p. 301-317
17 p.
 article
6 Analytical considerations for microdialysis sampling Davies, Malonne I
 2000
 69-70 2-3 p. 169-188
20 p.
 article
7 A novel chemical delivery system for brain targeting Yoshikawa, Takayoshi
 1999
 69-70 2-3 p. 255-275
21 p.
 article
8 Antibody-directed enzyme prodrug therapy (ADEPT): a review Niculescu-Duvaz, I
 1997
 69-70 2-3 p. 151-172
22 p.
 article
9 Antibody-targeted liposomes: prospects and problems Allen, T.M.
 1997
 69-70 2-3 p. 243-
1 p.
 article
10 Application of lipid microspheres for the treatment of cancer Takenaga, Mitsuko
 1996
 69-70 2-3 p. 209-219
11 p.
 article
11 Application of liposomes for cancer metastasis Oku, Naoto
 1997
 69-70 2-3 p. 215-223
9 p.
 article
12 Application of liposomes to the treatment of liver metastasis Konno, Hiroyuki
 1997
 69-70 2-3 p. 331-335
5 p.
 article
13 Application of microdialysis to characterize drug disposition in tumors Chu, Jianxiong
 2000
 69-70 2-3 p. 243-253
11 p.
 article
14 Approved indications of lipo-PGE1 in Japan Hoshi, K.
 1996
 69-70 2-3 p. 171-176
6 p.
 article
15 A preclinical assessment of the effect of lipo-PGE1 on thrombus formation and thrombus disaggregation Sim, A.K.
 1996
 69-70 2-3 p. 165-170
6 p.
 article
16 A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents ten Hagen, Timo L.M.
 1997
 69-70 2-3 p. 245-256
12 p.
 article
17 Biohybrid artificial pancreas based on macrocapsule device Hou, Q.P
 1999
 69-70 2-3 p. 271-287
17 p.
 article
18 Biological factors involved in blood clearance of liposomes by liver Liu, Dexi
 1997
 69-70 2-3 p. 201-213
13 p.
 article
19 Block copolymer micelles as long-circulating drug vehicles Kwon, Glen S.
 1995
 69-70 2-3 p. 295-309
15 p.
 article
20 Blood-brain barrier function of P-glycoprotein Tsuji, Akira
 1997
 69-70 2-3 p. 287-298
12 p.
 article
21 Blood–brain barrier permeability to small and large molecules Cornford, Eain M.
 1999
 69-70 2-3 p. 145-163
19 p.
 article
22 Blood microdialysis in pharmacokinetic and drug metabolism studies Verbeeck, Roger K
 2000
 69-70 2-3 p. 217-228
12 p.
 article
23 Carrier-mediated or specialized transport of drugs across the blood–brain barrier Tsuji, Akira
 1999
 69-70 2-3 p. 277-290
14 p.
 article
24 Cationic lipid–DNA complexes in gene delivery: from biophysics to biological applications Pedroso de Lima, Maria C
 2001
 69-70 2-3 p. 277-294
18 p.
 article
25 Cell cycle regulation and control of angioplasty restenosis Welt, Frederick G.P.
 1997
 69-70 2-3 p. 301-307
7 p.
 article
26 Challenges of turning nucleic acids into therapeutics Mahato, Ram I
 2000
 69-70 2-3 p. 79-80
2 p.
 article
27 Chemical delivery systems and prodrugs of anticonvulsive drugs Shek, Efraim
 1994
 69-70 2-3 p. 227-241
15 p.
 article
28 Chemistry of polyethylene glycol conjugates with biologically active molecules Zalipsky, Samuel
 1995
 69-70 2-3 p. 157-182
26 p.
 article
29 Compartment modeling Holz, Martin
 2001
 69-70 2-3 p. 249-264
16 p.
 article
30 Computer-assisted drug design and selection Kaminski, James J.
 1994
 69-70 2-3 p. 331-337
7 p.
 article
31 Contents of volume 14 1994
 69-70 2-3 p. 341-342
2 p.
 article
32 Contents of volume 8 1992
 69-70 2-3 p. 383-
1 p.
 article
33 Contents of volume 10 1993
 69-70 2-3 p. 319-
1 p.
 article
34 Contents of volume 9 1992
 69-70 2-3 p. 318-
1 p.
 article
35 Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery Hebert, M.F
 1997
 69-70 2-3 p. 201-214
14 p.
 article
36 Control-relevant modeling in drug delivery Parker, Robert S.
 2001
 69-70 2-3 p. 211-228
18 p.
 article
37 Cubic phase gels as drug delivery systems Shah, Jaymin C
 2001
 69-70 2-3 p. 229-250
22 p.
 article
38 Cumulative author index 1992
 69-70 2-3 p. 367-374
8 p.
 article
39 Cumulative key word index 1994
 69-70 2-3 p. 343-355
13 p.
 article
40 Cumulative key word index 1993
 69-70 2-3 p. 309-317
9 p.
 article
41 Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment 1 Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides. 1 Jeandidier, Nathalie
 1999
 69-70 2-3 p. 179-198
20 p.
 article
42 Delivery of anti-HIV nucleosides to the central nervous system Gallo, James M.
 1994
 69-70 2-3 p. 199-209
11 p.
 article
43 Delivery of molecular and cellular medicine to solid tumors Jain, Rakesh K
 1997
 69-70 2-3 p. 71-90
20 p.
 article
44 Delivery of peptides and proteins through the blood-brain barrier Bickel, Ulrich
 1993
 69-70 2-3 p. 205-245
41 p.
 article
45 Delivery of tumor suppressor genes to reverse the malignant phenotype Gibson, Neil W
 1997
 69-70 2-3 p. 119-133
15 p.
 article
46 Distribution of lipid microsphere preparations Igarashi, R.
 1996
 69-70 2-3 p. 147-154
8 p.
 article
47 DNA-carrier proteins for targeted gene delivery Uherek, Christoph
 2000
 69-70 2-3 p. 153-166
14 p.
 article
48 (D) Routes of delivery: Case studies de Boer, A.G.
 1992
 69-70 2-3 p. 237-251
15 p.
 article
49 (D) Routes of delivery: Case studies Richardson, Julie L.
 1992
 69-70 2-3 p. 341-366
26 p.
 article
50 (D) Routes of delivery: Case studies Harris, David
 1992
 69-70 2-3 p. 331-339
9 p.
 article
51 (D) Routes of delivery: Case studies Ho, N.F.H.
 1992
 69-70 2-3 p. 197-236
40 p.
 article
52 (D) Routes of delivery: Case studies Edman, Peter
 1992
 69-70 2-3 p. 165-177
13 p.
 article
53 (D) Routes of delivery: Case studies Smith, Philip L.
 1992
 69-70 2-3 p. 253-290
38 p.
 article
54 (D) Routes of delivery: Case studies Cullander, Christopher
 1992
 69-70 2-3 p. 291-329
39 p.
 article
55 (D) Routes of delivery: Case studies Patton, John S.
 1992
 69-70 2-3 p. 179-196
18 p.
 article
56 Drug design strategies for ocular therapeutics Visor, G.C.
 1994
 69-70 2-3 p. 269-279
11 p.
 article
57 Drug targeting and retrometabolic drug design approaches Introduction Bodor, N.
 1994
 69-70 2-3 p. 157-166
10 p.
 article
58 Drug transfer through mucus Khanvilkar, Kavita
 2001
 69-70 2-3 p. 173-193
21 p.
 article
59 Editorial 1997
 69-70 2-3 p. 97-98
2 p.
 article
60 Editorial 1998
 69-70 2-3 p. 121-
1 p.
 article
61 Editorial 1999
 69-70 2-3 p. 141-142
2 p.
 article
62 Editorial 1999
 69-70 2-3 p. 143-144
2 p.
 article
63 Editorial Board 2007
 69-70 2-3 p. ii-
1 p.
 article
64 Electrochemotherapy: an emerging drug delivery method for the treatment of cancer Jaroszeski, Mark J
 1997
 69-70 2-3 p. 185-197
13 p.
 article
65 Emulsion formulations as a vector for gene delivery in vitro and in vivo Hara, Toshifumi
 1997
 69-70 2-3 p. 265-271
7 p.
 article
66 Endogenous carriers and ligands in non-immunogenic site-specific drug delivery Vyas, S.P
 2000
 69-70 2-3 p. 101-164
64 p.
 article
67 Endogenous lectins as targets for drug delivery Yamazaki, N.
 2000
 69-70 2-3 p. 225-244
20 p.
 article
68 Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction Thummel, Kenneth E.
 1997
 69-70 2-3 p. 99-127
29 p.
 article
69 Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain Estes, K.S.
 1994
 69-70 2-3 p. 167-175
9 p.
 article
70 Evaluation of nano- and microparticle uptake by the gastrointestinal tract Delie, Florence
 1998
 69-70 2-3 p. 221-233
13 p.
 article
71 Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides Meade, Bryan R.
 2007
 69-70 2-3 p. 134-140
7 p.
 article
72 Exogenous surfactant as a drug delivery agent Haitsma, Jack J.
 2001
 69-70 2-3 p. 197-207
11 p.
 article
73 Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research Krafft, Marie Pierre
 2001
 69-70 2-3 p. 209-228
20 p.
 article
74 Forthcoming articles 1992
 69-70 2-3 p. 375-
1 p.
 article
75 Forthcoming articles 1993
 69-70 2-3 p. 301-303
3 p.
 article
76 Forthcoming articles 1992
 69-70 2-3 p. 313-314
2 p.
 article
77 Forthcoming events 1992
 69-70 2-3 p. 377-382
6 p.
 article
78 Forthcoming events 1992
 69-70 2-3 p. 315-317
3 p.
 article
79 Forthcoming events 1994
 69-70 2-3 p. 340-
1 p.
 article
80 Forthcoming events 1993
 69-70 2-3 p. 305-307
3 p.
 article
81 Forthcoming issues 1994
 69-70 2-3 p. 339-
1 p.
 article
82 Gene directed enzyme prodrug therapy for cancer McNeish, I.A
 1997
 69-70 2-3 p. 173-184
12 p.
 article
83 Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications Kumar, Lekha Dinesh
 2007
 69-70 2-3 p. 87-100
14 p.
 article
84 Gene therapy of chronic inflammatory disease Hedley, Mary Lynne
 2000
 69-70 2-3 p. 195-207
13 p.
 article
85 Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters Meijer, D.K.F.
 1997
 69-70 2-3 p. 159-200
42 p.
 article
86 How are nucleic acids released in cells from cationic lipid-nucleic acid complexes? Szoka Jr, Francis C.
 1997
 69-70 2-3 p. 291-
1 p.
 article
87 Human immunodeficiency virus protease inhibitors Lin, Jiunn H.
 1997
 69-70 2-3 p. 215-233
19 p.
 article
88 Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs Storm, Gert
 1997
 69-70 2-3 p. 225-231
7 p.
 article
89 Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs 1 Supported by the Robert Bosch Foundation, Stuttgart, Germany. 1 Fromm, Martin F
 1997
 69-70 2-3 p. 171-199
29 p.
 article
90 Improved brain delivery of antiviral agents through the use of redox targeting Brewster, M.E.
 1994
 69-70 2-3 p. 177-197
21 p.
 article
91 Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies Pauletti, Giovanni M.
 1997
 69-70 2-3 p. 235-256
22 p.
 article
92 Inhaled insulin 1 Abbreviations: DM, diabetes mellitus; AIDs, acquired immune deficiency syndrome; SC, subcutaneous; DCCT, Diabetes Control and Complications Trial; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; i.v., intravenous; DDPC, di-decanoyl-alpha-phosphatidylcholine; AUC, area under the curve; INH, inhaled; C max, maximum serum concentration; C min, minimum serum concentration; T max, time of maximum serum concentration; NS, not significant; HbA1c, hemoglobin A1c; OA, oral agent; SD, standard deviation; MDI, metered dose inhaler; DPI, dry powder inhaler; MMAD, mass median aerodynamic diameter; CMC, critical micelle concentration; SR, sustained release; PLGA, poly lactic acid-co-glycolic acid; GI, gastrointestinal, GSD, geometric standard deviation; TLC, total lung capacity; VC, vital capacity; SMK, smokers; MW, molecular weight; MP, melting point. 1 Patton, John S.
 1999
 69-70 2-3 p. 235-247
13 p.
 article
93 Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents Eileen Dolan, M
 1997
 69-70 2-3 p. 105-118
14 p.
 article
94 Inhibitors of glutathione S-transferases as therapeutic agents Schultz, Mary
 1997
 69-70 2-3 p. 91-104
14 p.
 article
95 Insulin analogs with improved pharmacokinetic profiles Brange, Jens
 1999
 69-70 2-3 p. 307-335
29 p.
 article
96 Interaction of PEG-phospholipid conjugates with phospholipid: implications in liposomal drug delivery Bedu-Addo, Frank K.
 1995
 69-70 2-3 p. 235-247
13 p.
 article
97 Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption Hunter, Janice
 1997
 69-70 2-3 p. 129-157
29 p.
 article
98 Intranasal insulin delivery and therapy 1 Abbreviations: α-CD, α-cyclodextrin; β-CD, β-cyclodextrin; γ-CD, γ-cyclodextrin; AUC, area under the plasma/serum concentration versus time curve; C max, maximum or peak plasma/serum concentration; C min, minimum plasma/serum concentration; DDPC, didecanoyl-L-α-phosphatidylcholine; DM-β-CD, dimethyl-β-cyclodextrin; EDTA, ethylenediaminetetraacetic acid; FITC, fluorescein isothiocyanate; HLB, hydrophile–lipophile balance; hGH, human growth hormone; HP-β-CD, hydroxy-propyl-β-cyclodextrin; HPC, hydroxypropylcellulose; HSA, human serum albumin; Hyaff 11, hyaluronic acid ester; IDDM, insulin-dependent diabetes mellitus; Ig, immunoglobulin; Laureth-9, polyoxyethylene-9-lauryl ether; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol; MCC, microcrystalline cellulose; MTR, mucociliary transport rate; NIDDM, non-insulin-dependent diabetes mellitus; PC, phosphatidylcholine; RAMEB, randomly methylated β-cyclodextrin; SDC, sodium deoxycholate; SGC, sodium glycocholate; STDHF, sodium taurodihydrofusidate; 99mTc, 99mtechnetium; TER, transepithelial resistance. 1 Hinchcliffe, Michael
 1999
 69-70 2-3 p. 199-234
36 p.
 article
99 In vitro model for evaluating drug transport across the blood–brain barrier Cecchelli, R
 1999
 69-70 2-3 p. 165-178
14 p.
 article
100 Key word index to volume 9 1992
 69-70 2-3 p. 309-312
4 p.
 article
101 Lectin-mediated mucosal delivery of drugs and microparticles Clark, M.Ann
 2000
 69-70 2-3 p. 207-223
17 p.
 article
102 Ligand-mediated tissue specific drug delivery Hussain, Nasir
 2000
 69-70 2-3 p. 95-100
6 p.
 article
103 Limethason as a lipid microsphere preparation: An overview Yokoyama, K.
 1996
 69-70 2-3 p. 195-201
7 p.
 article
104 Lipid Assemblies for Drug Delivery 2001
 69-70 2-3 p. 137-138
2 p.
 article
105 Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates Bally, Marcel B.
 1997
 69-70 2-3 p. 275-290
16 p.
 article
106 Lipid microsphere preparation of a prostacyclin analogue Kurozumi, S.
 1996
 69-70 2-3 p. 181-187
7 p.
 article
107 Lipid microspheres as drug carriers: a pharmaceutical point of view Yamaguchi, Tetsuo
 1996
 69-70 2-3 p. 117-130
14 p.
 article
108 Lipid microspheres (lipid emulsions) as a drug carrier — An overview Mizushima, Yutaka
 1996
 69-70 2-3 p. 113-115
3 p.
 article
109 Lipo-NSAID preparation Ohmukai, O.
 1996
 69-70 2-3 p. 203-207
5 p.
 article
110 Lipo-PGE1 treatment of the neonate with critical congenital heart disease and ductus-arteriosus dependent circulation Momma, Kazuo
 1996
 69-70 2-3 p. 177-180
4 p.
 article
111 Liposome circulation time and tumor targeting: implications for cancer chemotherapy Gabizon, Alberto A.
 1995
 69-70 2-3 p. 285-294
10 p.
 article
112 Liposomes in gene therapy Lasic, D.D.
 1996
 69-70 2-3 p. 221-266
46 p.
 article
113 Liposome turbidimetric assay (LTA) Ueno, Takahisa
 1997
 69-70 2-3 p. 293-299
7 p.
 article
114 Local delivery of chemotherapy: a supplement to existing cancer treatments Hunter, William L
 1997
 69-70 2-3 p. 199-207
9 p.
 article
115 Long-circulating blood pool imaging agents Bogdanov Jr., Alexei A.
 1995
 69-70 2-3 p. 335-348
14 p.
 article
116 Long-circulating iron oxides for MR imaging Weissleder, Ralph
 1995
 69-70 2-3 p. 321-334
14 p.
 article
117 Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals Gabizon, Alberto
 1997
 69-70 2-3 p. 337-344
8 p.
 article
118 Long circulating microparticulate drug carriers Stolnik, S.
 1995
 69-70 2-3 p. 195-214
20 p.
 article
119 Mathematical modeling of bioerodible, polymeric drug delivery systems Siepmann, J.
 2001
 69-70 2-3 p. 229-247
19 p.
 article
120 Mathematical modeling of controlled drug delivery 2001
 69-70 2-3 p. 137-138
2 p.
 article
121 Mathematical models describing polymer dissolution: consequences for drug delivery Narasimhan, Balaji
 2001
 69-70 2-3 p. 195-210
16 p.
 article
122 MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport Frijters, Charles M.G.
 1997
 69-70 2-3 p. 201-215
15 p.
 article
123 Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers Moghimi, S.M.
 1995
 69-70 2-3 p. 183-193
11 p.
 article
124 Methodological issues in microdialysis sampling for pharmacokinetic studies de Lange, Elizabeth C.M.
 2000
 69-70 2-3 p. 125-148
24 p.
 article
125 Microdialysis and drug delivery to the eye Rittenhouse, Kay D
 2000
 69-70 2-3 p. 229-241
13 p.
 article
126 Microdialysis for pharmacokinetic analysis of drug transport to the brain de Lange, Elizabeth C.M.
 1999
 69-70 2-3 p. 211-227
17 p.
 article
127 Microdialysis in clinical drug delivery studies Müller, Markus
 2000
 69-70 2-3 p. 255-269
15 p.
 article
128 Microdialysis in mice for drug delivery research Boschi, Gabrielle
 2000
 69-70 2-3 p. 271-281
11 p.
 article
129 Microdialysis in peripheral tissues de la Peña, Amparo
 2000
 69-70 2-3 p. 189-216
28 p.
 article
130 Microdialysis in the study of drug transporters in the CNS Sawchuk, Ronald J
 2000
 69-70 2-3 p. 295-307
13 p.
 article
131 Microparticles and polymers for the mucosal delivery of vaccines O'Hagan, Derek T.
 1998
 69-70 2-3 p. 305-320
16 p.
 article
132 Microparticle targeting to M cells Ermak, Thomas H
 1998
 69-70 2-3 p. 261-283
23 p.
 article
133 Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo) Papisov, Mikhail I.
 1995
 69-70 2-3 p. 127-139
13 p.
 article
134 Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC) Siepmann, J
 2001
 69-70 2-3 p. 139-157
19 p.
 article
135 Modeling transdermal drug release Kalia, Yogeshvar N.
 2001
 69-70 2-3 p. 159-172
14 p.
 article
136 Model systems in iontophoresis — transport efficacy Sage Jr., Burton H.
 1992
 69-70 2-3 p. 265-287
23 p.
 article
137 Modulation of pharmacokinetic behavior of liposomes Scherphof, Gerrit L.
 1997
 69-70 2-3 p. 179-191
13 p.
 article
138 Molecular conformation and structural reorganization near the lipid bilayer surface: biophysical studies of ‘long-circulating’ and DNA-carrying membranes Cevc, Gregor
 1997
 69-70 2-3 p. 233-
1 p.
 article
139 Mucosal immunity of the gastrointestinal tract and oral tolerance Simecka, Jerry W
 1998
 69-70 2-3 p. 235-259
25 p.
 article
140 Nano- and microparticles for the delivery of polypeptides and proteins Couvreur, P.
 1993
 69-70 2-3 p. 141-162
22 p.
 article
141 New lipo-PGE1 using a stable prodrug of prostaglandin E1 (PGE1) Igarashi, R.
 1996
 69-70 2-3 p. 189-194
6 p.
 article
142 Noncompartmentally-based pharmacokinetic modeling Veng-Pedersen, Peter
 2001
 69-70 2-3 p. 265-300
36 p.
 article
143 Non-viral siRNA delivery to the lung Thomas, Mini
 2007
 69-70 2-3 p. 124-133
10 p.
 article
144 Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye Reddy, Indra K.
 1994
 69-70 2-3 p. 251-267
17 p.
 article
145 Oligonucleotide therapeutics: lessons from sterically stabilized liposomes Woodle, M.C.
 1997
 69-70 2-3 p. 273-
1 p.
 article
146 On mathematical models of microdialysis: geometry, steady-state models, recovery and probe radius Ståhle, Lars
 2000
 69-70 2-3 p. 149-167
19 p.
 article
147 Opportunities and challenges for therapeutic gene silencing using RNAi and microRNA technologies Akhtar, Saghir
 2007
 69-70 2-3 p. 73-74
2 p.
 article
148 Oral insulin delivery 1 Abbreviations: GI, gastrointestinal; IDDM, insulin-dependent diabetes mellitus; IU, international units; NIDDM, non-insulin-dependent diabetes mellitus; PIN, phase inversion nanoencapsulation; ZOT, zona occludens toxin. 1 Carino, Gerardo P
 1999
 69-70 2-3 p. 249-257
9 p.
 article
149 Oral particulate delivery: status and future trends Chen, Hongming
 1998
 69-70 2-3 p. 339-350
12 p.
 article
150 Pathogenesis of non-insulin-dependent (type II) diabetes mellitus (NIDDM) – genetic predisposition and metabolic abnormalities Jun, Hee-Sook
 1999
 69-70 2-3 p. 157-177
21 p.
 article
151 Pathogenesis, prediction and trials for the prevention of insulin-dependent (type 1) diabetes mellitus 1 Abbreviations: s.c., subcutaneous; i.p., intraperitoneal; i.v., intravenous; IFA, incomplete Freund's adjuvant; DTP, diphtheria-tetanus-pertussis; LCMV, lymphocytic choriomeningitis virus; GAD, glutamic acid decarboxylase; ICA, islet cell autoantibody; JDF, juvenile diabetes foundation; IAA, insulin autoantibody; GAA, glutamic acid decarboxylase autoantibody; DM, diabetes mellitus; RIA, radioimmunoassay; AA, autoantibody; kD, kilodalton; FPIR, first phase insulin release; IIF, indirect immunofluoresence; IGT, impaired glucose tolerance; OGT, oral glucose tolerance. 1 Graves, Patricia M.
 1999
 69-70 2-3 p. 143-156
14 p.
 article
152 Penetration of neurotrophins and cytokines across the blood–brain/blood–spinal cord barrier Pan, Weihong
 1999
 69-70 2-3 p. 291-298
8 p.
 article
153 Peptide nucleic acids: versatile tools for gene therapy strategies Dean, David A
 2000
 69-70 2-3 p. 81-95
15 p.
 article
154 P-Glycoprotein, a gatekeeper in the blood–brain barrier Schinkel, Alfred H
 1999
 69-70 2-3 p. 179-194
16 p.
 article
155 Pharmacokinetics of long-circulating liposomes Allen, Theresa M.
 1995
 69-70 2-3 p. 267-284
18 p.
 article
156 Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes Sadzuka, Yasuyuki
 1997
 69-70 2-3 p. 257-263
7 p.
 article
157 Physiological considerations in the design of particulate dosage forms for oral vaccine delivery Yeh, Ping-Yang
 1998
 69-70 2-3 p. 123-133
11 p.
 article
158 Plasma factors affecting disposition of liposomes Kiwada, Hiroshi
 1997
 69-70 2-3 p. 193-199
7 p.
 article
159 Polymeric carriers for oral uptake of microparticulates Andrianov, Alexander K
 1998
 69-70 2-3 p. 155-170
16 p.
 article
160 Polymeric implants for cancer chemotherapy Fung, Lawrence K.
 1997
 69-70 2-3 p. 209-230
22 p.
 article
161 Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics Allémann, Eric
 1998
 69-70 2-3 p. 171-189
19 p.
 article
162 Polymers for controlled parenteral delivery of peptides and proteins Heller, Jorge
 1993
 69-70 2-3 p. 163-204
42 p.
 article
163 Preface Gibson, N.W
 1997
 69-70 2-3 p. 69-70
2 p.
 article
164 Preface Pitt, C.G.
 1993
 69-70 2-3 p. vii-
1 p.
 article
165 Preface Guy, Richard H.
 1992
 69-70 2-3 p. vii-viii
nvt p.
 article
166 Preface Torchilin, Vladimir P.
 1995
 69-70 2-3 p. 125-126
2 p.
 article
167 Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems Bodor, Nicholas
 1999
 69-70 2-3 p. 229-254
26 p.
 article
168 Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting Rensen, Patrick C.N
 2001
 69-70 2-3 p. 251-276
26 p.
 article
169 Renal secretion of organic cations: a multistep process Pritchard, John B.
 1997
 69-70 2-3 p. 231-242
12 p.
 article
170 Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease Simmons, Nicholas L.
 1997
 69-70 2-3 p. 243-256
14 p.
 article
171 Renal tubular secretion of organic anions Dantzler, William H.
 1997
 69-70 2-3 p. 217-230
14 p.
 article
172 Ribozyme and peptide–nucleic acid-based gene therapy Phylactou, Leonidas A
 2000
 69-70 2-3 p. 97-108
12 p.
 article
173 RNA interference and innate immunity Sioud, Mouldy
 2007
 69-70 2-3 p. 153-163
11 p.
 article
174 RNAi therapeutics: Principles, prospects and challenges Aagaard, Lars
 2007
 69-70 2-3 p. 75-86
12 p.
 article
175 RNA repair: a novel approach to gene therapy Watanabe, Takashi
 2000
 69-70 2-3 p. 109-118
10 p.
 article
176 Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system Suzuki, Hiroshi
 1997
 69-70 2-3 p. 257-285
29 p.
 article
177 Role of saccharides for the freeze-thawing and freeze drying of liposome Miyajima, Koichiro
 1997
 69-70 2-3 p. 151-159
9 p.
 article
178 Roles of lipid polymorphism in intracellular delivery Hafez, Ismail M.
 2001
 69-70 2-3 p. 139-148
10 p.
 article
179 Screening and biological evaluation of liposomal formulations containing Adriamycin® Yachi, Kiyoto
 1997
 69-70 2-3 p. 123-131
9 p.
 article
180 Selective boron drug delivery to brain tumors for boron neutron capture therapy Chen, Wei
 1997
 69-70 2-3 p. 231-247
17 p.
 article
181 shRNA and siRNA delivery to the brain Pardridge, William M.
 2007
 69-70 2-3 p. 141-152
12 p.
 article
182 Site-specific insulin conjugates with enhanced stability and extended action profile Uchio, Takashi
 1999
 69-70 2-3 p. 289-306
18 p.
 article
183 Skin biological issues in electrically enhanced transdermal delivery Ledger, Philip W.
 1992
 69-70 2-3 p. 289-307
19 p.
 article
184 Soft anticholinergics Hammer, R.H.
 1994
 69-70 2-3 p. 281-292
12 p.
 article
185 Solid lipid nanoparticles Mehnert, Wolfgang
 2001
 69-70 2-3 p. 165-196
32 p.
 article
186 Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract Ponchel, Gilles
 1998
 69-70 2-3 p. 191-219
29 p.
 article
187 Stability of lipid emulsions for drug delivery Washington, C.
 1996
 69-70 2-3 p. 131-145
15 p.
 article
188 Stealth® liposomes: from theory to product Cˇeh, Boris
 1997
 69-70 2-3 p. 165-177
13 p.
 article
189 Sterically stabilized liposome therapeutics Woodle, Martin C.
 1995
 69-70 2-3 p. 249-265
17 p.
 article
190 Structure-transport relationships in transdermal iontophoresis Yoshida, Nagahiro H.
 1992
 69-70 2-3 p. 239-264
26 p.
 article
191 Studies on two new lymph imaging agents and their clinical application Ma, Yuan-Ming
 1997
 69-70 2-3 p. 315-323
9 p.
 article
192 Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B Hillery, Anya M.
 1997
 69-70 2-3 p. 345-363
19 p.
 article
193 Surface-modified liposomes in gamma- and MR-imaging Torchilin, Vladimir P.
 1997
 69-70 2-3 p. 301-313
13 p.
 article
194 Systemic siRNA delivery via hydrodynamic intravascular injection Lewis, David L.
 2007
 69-70 2-3 p. 115-123
9 p.
 article
195 Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals Maruyama, Kazuo
 1997
 69-70 2-3 p. 235-242
8 p.
 article
196 Targeting penicillins to the central nervous system: chemical delivery systems and redox analogs Pop, E.
 1994
 69-70 2-3 p. 211-226
16 p.
 article
197 The barrier function of CYP3A4 and P-glycoprotein in the small bowel Watkins, Paul B
 1997
 69-70 2-3 p. 161-170
10 p.
 article
198 The blood–brain barrier efflux transporters as a detoxifying system for the brain Terasaki, Tetsuya
 1999
 69-70 2-3 p. 195-209
15 p.
 article
199 The brain-targeted delivery of dopamine using a redox-based chemical delivery system Simpkins, James W.
 1994
 69-70 2-3 p. 243-249
7 p.
 article
200 The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres Gref, R.
 1995
 69-70 2-3 p. 215-233
19 p.
 article
201 The design and development of DaunoXome® for solid tumor targeting in vivo Forssen, Eric A.
 1997
 69-70 2-3 p. 133-150
18 p.
 article
202 The distribution and chemical kinetics of prostaglandin E1 in lipid emulsions Teagarden, Dirk L.
 1996
 69-70 2-3 p. 155-164
10 p.
 article
203 The effect of physical barriers and properties on the oral absorption of particulates Norris, Daniel A
 1998
 69-70 2-3 p. 135-154
20 p.
 article
204 The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans Wilkinson, Grant R
 1997
 69-70 2-3 p. 129-159
31 p.
 article
205 Theoretical models for iontophoretic delivery Kasting, Gerald B.
 1992
 69-70 2-3 p. 177-199
23 p.
 article
206 The pharmaceutics and delivery of therapeutic polypeptides and proteins Talmadge, James E.
 1993
 69-70 2-3 p. 247-299
53 p.
 article
207 The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids Loftsson, Thorsteinn
 1994
 69-70 2-3 p. 293-299
7 p.
 article
208 The preparation and characterization of polymeric antigen delivery systems for oral administration Singh, Manmohan
 1998
 69-70 2-3 p. 285-304
20 p.
 article
209 Therapeutic potential for microRNAs Esau, Christine C.
 2007
 69-70 2-3 p. 101-114
14 p.
 article
210 The role of CpG motifs in immunostimulation and gene therapy Scheule, Ronald K
 2000
 69-70 2-3 p. 119-134
16 p.
 article
211 The role of electroosmotic flow in transdermal iontophoresis Pikal, Michael J.
 1992
 69-70 2-3 p. 201-237
37 p.
 article
212 The use of microdialysis in CNS drug delivery studies Hammarlund-Udenaes, Margareta
 2000
 69-70 2-3 p. 283-294
12 p.
 article
213 The use of phage display for the development of tumour targeting agents Nilsson, Fredrik
 2000
 69-70 2-3 p. 165-196
32 p.
 article
214 Three-dimensional liposome networks: freeze fracture electron microscopical evaluation of their structure and in vitro analysis of release of hydrophilic markers Brandl, M.
 1997
 69-70 2-3 p. 161-164
4 p.
 article
215 Tissue engineering via local gene delivery: Bonadio, Jeffrey
 2000
 69-70 2-3 p. 185-194
10 p.
 article
216 Toward development of a non-viral gene therapeutic Smith, Janet
 1997
 69-70 2-3 p. 135-150
16 p.
 article
217 Toward lung-selective β2-adrenergic bronchodilator prodrugs Svensson, Leif-Å.
 1994
 69-70 2-3 p. 319-330
12 p.
 article
218 Towards new products for human health Hirota, Sadao
 1997
 69-70 2-3 p. 121-122
2 p.
 article
219 Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity Akhtar, Saghir
 2007
 69-70 2-3 p. 164-182
19 p.
 article
220 Transcriptional control: an essential component of cancer gene therapy strategies? Harrington, Kevin J.
 2000
 69-70 2-3 p. 167-184
18 p.
 article
221 Transdermal ion migration Bradley Phipps, J.
 1992
 69-70 2-3 p. 137-176
40 p.
 article
222 Treatment of type I diabetes using encapsulated islets 1 Abbreviations: Tx, transplantation; IEQ, islet equivalent; BUN, blood urea nitrogen. 1 Soon-Shiong, Patrick
 1999
 69-70 2-3 p. 259-270
12 p.
 article
223 Uptake and adjuvant activity of orally delivered saponin and ISCOM™ vaccines Sjölander, Anders
 1998
 69-70 2-3 p. 321-338
18 p.
 article
224 Use of microdialysis in drug delivery studies Elmquist, William F
 2000
 69-70 2-3 p. 123-124
2 p.
 article
225 Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents Trubetskoy, Vladimir S.
 1995
 69-70 2-3 p. 311-320
10 p.
 article
226 Vector-mediated drug delivery to the brain Pardridge, William M.
 1999
 69-70 2-3 p. 299-321
23 p.
 article
227 Virosomes: evolution of the liposome as a targeted drug delivery system Kaneda, Yasufumi
 2000
 69-70 2-3 p. 197-205
9 p.
 article
228 What are the pathways of iontophoretic current flow through mammalian skin? Cullander, Christopher
 1992
 69-70 2-3 p. 119-135
17 p.
 article
229 Which polymers can make nanoparticulate drug carriers long-circulating? Torchilin, Vladimir P.
 1995
 69-70 2-3 p. 141-155
15 p.
 article
                             229 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands